Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GlaxoSmithKline's asthma inhaler Seretide has won a European license extension for use in a wider population of patients with chronic obstructive pulmonary disease.
Subscribe to our email newsletter
The inhaler, which is GSK’s top-selling product, is used for treating COPD, a lung disease comprised of chronic bronchitis and emphysema.
The approval was granted following a regulatory review of a clinical study known as TORCH, which investigated the drug’s use among patients with COPD.
Seretide, which is marketed as Advair in the United States, generated worldwide sales of GBP3.3 billion in 2006.